(CAPR) Capricor Therapeutics - Ratings and Ratios

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company pioneering the development of innovative cell and exosome-based therapies. The company’s primary focus is on addressing Duchenne muscular dystrophy (DMD), a severe genetic disorder characterized by progressive muscle degeneration, as well as other conditions with significant unmet medical needs. Capricor’s lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy designed to support cardiac function in late-stage DMD patients. This therapy has advanced to a Phase 3 clinical trial, marking a critical milestone in its development.

Capricor is also exploring the potential of exosome-based technologies through its StealthX platform, which is currently in Phase 1 clinical studies. StealthX is an engineered exosome-based vaccine candidate with broad therapeutic applications, including the delivery of targeted RNA, protein, and small molecule therapies. This platform holds promise for treating a wide range of diseases by leveraging the unique properties of exosomes, which are naturally occurring extracellular vesicles capable of delivering therapeutic payloads to specific tissues.

In addition to its clinical-stage programs, Capricor is advancing CAP-2003, a pre-clinically developed therapy aimed at addressing trauma-related injuries and conditions. The company has established a robust network of collaborations, including agreements with Nippon Shinyaku Co. Ltd., the National Institute of Allergy and Infectious Diseases, Johns Hopkins University, Cedars-Sinai Medical Center, and Life Technologies Corporation. These partnerships underscore Capricor’s commitment to accelerating innovation and expanding its therapeutic pipeline.

Founded in 2005 and headquartered in San Diego, California, Capricor operates at the intersection of regenerative medicine and precision therapeutics. Its focus on cell and exosome-based approaches positions the company as a key player in the evolving landscape of biotechnology. For more information, visit their website at https://www.capricor.com.

From a valuation perspective, Capricor’s market capitalization of $688.87 million reflects investor confidence in its pipeline and technology. The company’s price-to-book (P/B) ratio of 10.05 indicates a significant premium over its book value, suggesting that investors are pricing in future growth potential